2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5261 Multi-omic classification of T-cell lymphoblastic lymphoma for driver and subtype identification

Lahari Uppuluri, PhD, Haley Newman, MD, MSCE2, Rawan Shraim, PhD3, Ritu Roy4, Selma Sammy Shraim5, Donald Barkauskas, PhD6, Kara L. Davis, D.O.7, Meenakshi Devidas, PhD8, Caroline Diorio, MD9, Kimberly Dunsmore, MD10, Carol Fries Simpson, MD11, Lia Gore, MD12, Thomas Gross, MD13, Robert J. Hayashi14, Terzah Horton, MD , PhD15, Andrew Hughes, MD, PhD16, Stephen P. Hunger, MD17, Yimei Li, PhD18, Lingyun Ji, PhD19, Stephanie Si Lim, MD20, Mignon L. Loh, MD21, Ferro Nguyen, MSc22, Karen R. Rabin, MD, PhD23, Elizabeth A. Raetz, MD24, Rachel E. Rau, MD25, Kai Tan, PhD26, Stuart Winter27, Birte Wistinghausen, MD28, Brent L. Wood, PhD, MD29, Jason Xu, M.D./Ph.D.30, Jun J. Yang, PhD31, Carl Allen, MD32, Michelle L. Hermiston, MD , PhD33, Rodney Miles, MD, PhD34, Adam Olshen, PhD35, Charles G. Mullighan, MBBS (Hons), MSc, MD36, Petri Polonen, PhD37, David T. Teachey, MD38
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
5 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
6 Keck School of Medicine of the University of Southern California / Children's Oncology Group, Monrovia, California, United States
7 Stanford University School of Medicine, Stanford, California, United States
8 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
9 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
10 University of Virginia Health Sciences Center, Charlottesville, Virginia, United States
11 University of Rochester Medical Center, Rochester, New York, United States
12 Center for Cancer and Blood Disorders, University of Colorado Cancer Center, Aurora, Colorado, United States
13 Phoenix Children's Hospital, phoenix, Arizona, United States
14 Washington University School of Medicine, St.Louis, Montana, United States
15 Baylor College of Medicine/ Dan L. Duncan Cancer Center Children's Cancer Center, Houston, Texas, United States
16 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
17 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
18 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
19 Children's Oncology Group and Keck School of Medicine of the University of Southern California, Monrovia, California, United States
20 John A. Burns School of Medicine, University of Hawai‘i, Honolulu, Hawaii, United States
21 Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, Fred Hutch Cancer Center, University of Washington, seattle, Washington, United States
22 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
23 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
24 NYU Grossman School of Medicine, New York, New York, United States
25 Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, Fred Hutch Cancer Center, University of Washington, seattle, Washington, United States
26 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
27 Cancer and Blood Disorders Center Children's Minnesota, Eagan, Minnesota, United States
28 Children's National Hospital, Washington DC, United States
29 Children's Hospital Los Angeles, Los Angeles, California, United States
30 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
31 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
32 Texas Children's Cancer Center, Houston, Texas, United States
33 University of California San Francisco Benioff Children's Hospital, San Francisco, California, United States
34 University of Utah, Salt Lake City, Utah, United States
35 University of California San Francisco, San Francisco, California, United States
36 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
37 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
38 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Introduction: T-cell lymphoblastic lymphoma (T-LBL) and T-cell acute lymphoblastic leukemia (T-ALL) have been considered a spectrum of the same disease based on overlapping immunophenotype and response to conventional chemotherapy. Over time, treatment regimens have harmonized; however, recent trials have demonstrated differential responses to novel therapies, including nelarabine and bortezomib, highlighting the importance of understanding differences between T-ALL and T-LBL. The molecular landscape of T-LBL is less well-characterized than T-ALL due to rarity, limited tissue availability, and lower tumor purity. We performed comprehensive genomic profiling on a large cohort of patients with T-LBL treated on Children’s Oncology Group clinical trials and compared these to similarly treated patients with T-ALL.  

 

Methods: Whole genome sequencing (WGS) and whole transcriptome (EdgeSeq) profiling were performed on 155 FFPE-preserved T-LBL samples from patients on AALL0434 (57%) and AALL1231 (43%). Genomic alterations in T-LBL were compared to those in our published cohort of 1309 T-ALL cases treated on AALL0434 (Polonen, Nature 2024). Somatic variant from Manta SV and Mutect2 SNV/indels were used as input for the TALLForest multiomic classifier for driver identification and subtype assignment. Between-cohort frequencies were compared using Fisher's exact test. 

 

Results: Driver alterations have been identified in 76.1% (n=118) of cases. TALLForest’s predicted subtype revealed enrichment for T-ALL genomic subtypes in patients with T-LBL, including TAL1 subtypes (DP-like, αβ-like, other; n=21), NKX2-1 (n=11), TLX3 (n=11), ETP-like (n=10), KMT2A-r (n=7), MLLT10 (n=7), and TLX1 (n=5), yet relative frequencies differed markedly from T-ALL. Compared to T-ALL, developmentally immature genomic subtypes were less frequent in T-LBL, including TLX3 (7.1% vs 16.9%; p=0.001) and ETP-like (6.5% vs 19.8%, p<0.001). T-LBL was enriched in MLLT10-rearranged/HOXA-pathway and NKX2-1 subtypes, with the latter marked by recurrent chr14 chromothripsis and BCL11B rearrangements, as in T-ALL-based classification schemes. A recurrent landscape of structural alterations, including rearrangements, fusions, and enhancer hijacking was observed in T-LBL, including TCR::NOTCH1, BCL11B::TLX3, TCRAD/TCRB::LMO2, KMT2A::MLLT1/AFDN, PICALM::MLLT10, IKZF2::NOTCH1, and ABL/SET::NUP214, among others. BCL11B (n=20 cases) was identified as a recurrent, promiscuous rearrangement hub, found juxtaposed with TLX3, NKX2-1, LMO2, HOXA13, FOXF1, and NKX2-5 with TCR loci (TCRAD/TCRB/TCRG) as the most frequent lesion partners. Rarer genomic subtypes (NUP214, NUP98, SPI1, NKX2-5, FOXF1/FENDRR) were each identified in fewer than 5 cases. Driver structural alterations involving TCR::NOTCH1 and IKZF2::NOTCH1 were more common in T-LBL, with TCR::NOTCH1 observed in 9.7% of the T-LBL vs. 0.15% of T-ALL (p<0.001), and IKZF2::NOTCH1 in 3.2% of T-LBL vs. 0% of T-ALL (p<0.001), suggesting that T-LBL harbors an expanded repertoire of NOTCH1-activating rearrangement partners beyond the canonical TCR-driven mechanism. FBXW7, a negative regulator of NOTCH1, was also structurally altered in a subset of cases (1.9% T-LBL vs. 0.7% T-ALL p=0.13). Integration of WGS and EdgeSeq data, as well as mechanistic studies, are underway to investigate functional relevance of these and other lesions in T-LBL and to identify drivers in the remaining cases. 

 

In Pölönen 2024, we also assigned T-ALL genomic alterations into groups based on variants that activate targetable pathways. Preliminary analysis in T-LBL demonstrated that epigenetic regulation was the most frequently altered targetable pathway category, followed by Ras signaling, whereas in T-ALL, cell cycle and NOTCH signaling were the most frequently altered. Initial integration with outcome data identified alterations associated with event-free survival in univariate analysis, including known and previously unreported prognostic alterations, such as TCR::NOTCH1 fusions (5-year EFS 73.3% vs 92.1% in cases with vs without, p<0.001) and IKZF2::NOTCH1 (80.0% vs 90.6% p=0.49), though did not reach statistical significance likely reflecting small numbers. 

 

Conclusion: Despite low tumor purity and tumor-only sequencing in most cases, we identified drivers in the majority of T-LBL cases, demonstrating differential enrichment of genomic subtypes relative to T-ALL, novel tumor biology, and differential impact on outcome. 

David T. Teachey, MD: BEAM - Research Funding; Syndax - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Astra Zeneca - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); J and J Innovation - Consultancy (Includes expert testimony); BEAM - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Jazz - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony)